DFT383
| Clinical data | |
|---|---|
| Drug class | gene therapy |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
DFT383 is an investigational gene therapy under development by Novartis for the treatment of cystinosis, a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, leading to cystine accumulation in cells.[1]
The therapy delivers a functional copy of the CTNS gene via autologous hematopoietic stem cell (HSC) transplantation to address the disease’s root cause, targeting patients both pre- and post-kidney transplant.[2]
Mechanism of action
DFT383 involves extracting a patient’s hematopoietic stem cells, genetically modifying them ex vivo with a lentiviral vector to insert a functional CTNS gene, and reinfusing them after myeloablation.[3]
The modified cells are intended to produce functional cystinosin, a lysosomal cystine-proton symporter, reducing cystine accumulation throughout the body, including in the kidneys, eyes, and other organs.[4]
In preclinical studies using Ctns−/− mice, treatment with lentiviral-based CTNS gene therapy resulted in significant reductions in tissue cystine levels and preservation of kidney, eye, and thyroid function.[5]
Development history
DFT383 was initially developed by AVROBIO as AVR-RD-04, with early clinical trials sponsored by the University of California, San Diego.[6]
A Phase I/II trial, approved by the FDA in November 2018, enrolled six adult patients and showed sustained engraftment, reduced leukocyte cystine levels, and improvements in visual and motor functions up to 36 months post-treatment, with patients discontinuing oral cysteamine.[7][8] No serious adverse events related to the therapy were reported.[7]
In May 2023, Novartis acquired DFT383 and all its associated intellectual property from AVROBIO for $87.5 million, to bolster its gene therapy pipeline.[9][10]
References
- ↑ "Cystinosis". GeneReviews. University of Washington, Seattle. December 7, 2017. Archived from the original on April 5, 2011. Retrieved May 27, 2025. Unknown parameter
|url-status=ignored (help) - ↑ Novartis Pharmaceuticals (May 6, 2025). An Open-label, Multi-center, Phase I/II Study to Assess Safety, Tolerability and Efficacy of DFT383 in Pediatric Participants With Nephropathic Cystinosis (Report). clinicaltrials.gov.
- ↑ Cherqui S (March 21, 2023). "Hematopoietic Stem Cell Gene Therapy for Cystinosis: From Bench-to-Bedside". Médecine/Sciences. 39 (3): 253–261. doi:10.1051/medsci/2023025. PMC 10629270 Check
|pmc=value (help). PMID 36943122 Check|pmid=value (help). - ↑ Bondue T, et al. (November 28, 2023). "Evaluation of the efficacy of cystinosin supplementation through CTNS mRNA delivery in experimental models for cystinosis". Scientific Reports. Nature. 13: 20961. doi:10.1038/s41598-023-47085-w. PMC 10684520 Check
|pmc=value (help). PMID 38016974 Check|pmid=value (help). - ↑ Cherqui S (2023). "Cystinosis: From the gene identification to the first gene therapy clinical trial". Médecine/Sciences. 39 (3): 253–261. doi:10.1051/medsci/2023025. PMC 10629270 Check
|pmc=value (help). PMID 36943122 Check|pmid=value (help). - ↑ "Novartis adding cystinosis gene therapy - BioProcess Insider". www.bioprocessintl.com. Retrieved May 27, 2025.
- ↑ 7.0 7.1 "AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis". AVROBIO. May 18, 2023. Retrieved May 27, 2025.
- ↑ "Research Overview". Cystinosis Research Foundation. October 10, 2019. Retrieved May 27, 2025.
- ↑ "Novartis buys rare disease gene therapy from Avrobio". BioPharma Dive. May 22, 2023. Retrieved May 27, 2025.
- ↑ "AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million". Business Wire. May 22, 2023. Retrieved May 27, 2025.
External links
This article "DFT383" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:DFT383. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
